Recently, the China Drug Clinical Trial Registration and Information Disclosure Platform announced that Takeda (TAK.US) has initiated two international multi-center (including China) phase 3 clinical studies of TAK-279 tablets, targeting moderate to severe plaque psoriasis.
The Zhitong Finance App learned that recently, the Chinese Drug Clinical Trial Registration and Information Dissemination Platform announced that Takeda (TAK.US) has launched two international multi-center (including China) phase 3 clinical studies of TAK-279 tablets. The indication is moderate to severe plaque psoriasis. According to public information, TAK-279 is a highly selective, oral allogeneic tyrosine kinase 2 (TYK2) inhibitor. In December 2022, Takeda acquired Nimbus Lakshmi and the TyK2 inhibitor it developed with an advance payment of $4 billion and a commercial milestone payment of $2 billion.
According to information, in addition to Takeda's TAK-279 tablets, many TYK2 inhibitors are being developed or have made breakthroughs in the treatment of psoriasis around the world. For example, deuterocloxitinib tablets have previously been approved in the US, China and other countries to treat plaque psoriasis. The dual-target TYK2/JAK1 inhibitor TLL-018 has achieved positive results in phase 1 clinical studies to treat psoriasis, and the TYK2-JH1 inhibitor ICP-332 and the TYK2-JH2 inhibitor ICP488 have also obtained positive data in psoriatic clinical studies.